ALMS
Alumis Inc
NASDAQ · Pharmaceuticals
$26.19
-0.15 (-0.57%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 878.33M | 917.39M | 923.52M |
| Net Income | 120.27M | 166.79M | 141.53M |
| EPS | — | — | — |
| Profit Margin | 13.7% | 18.2% | 15.3% |
| Rev Growth | +6.0% | +16.1% | -7.6% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 414.28M | 427.86M | 516.43M |
| Total Equity | 1.64B | 1.41B | 1.63B |
| D/E Ratio | 0.25 | 0.30 | 0.32 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 272.46M | 241.94M | 249.41M |
| Free Cash Flow | 126.96M | 147.40M | 173.90M |